RxDoctor Payments Data

Jamie Pierson

Family · Montrose, MINPI 1225751100

Payments from drug & device makers

$4,237in general payments, 2019–2025

Across 210 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$670
  • Novo Nordisk$508
  • Axsome Therapeutics, Inc.$454
  • Jazz Pharmaceuticals Inc.$379
  • Harmony Biosciences LLC$307
  • Otsuka America Pharmaceutical, Inc.$237
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,20499%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,237 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,852
MounjaroTirzepatide15$15,535
EliquisApixaban11$12,023
FarxigaDapagliflozin Propanediol11$8,847
Calcipotriene11$3,418
Piroxicam11$1,386
Atorvastatin Calcium86$784
Duloxetine Hcl17$657
Albuterol Sulfate HfaAlbuterol Sulfate19$653
Lisinopril78$446
Fluticasone Propionate38$423
Omeprazole28$382
Gabapentin52$352
Gemfibrozil11$339
Montelukast Sodium26$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$181$18,85225 claims
Lilly USA, LLCMounjaro$119$15,53515 claims
AstraZenecaFarxiga$670$8,84711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.

Other family in Montrose

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →